- Gilead Sciences (NASDAQ:GILD) has been working with regulatory authorities to start additional expanded access programs for remdesivir, its investigational medicine for COVID-19, Chairman and CEO Daniel O'Day wrote on the company's website.
- Such programs allow hospitals or physicians to apply for emergency use of the treatment for multiple severely ill patients at a time.
- Even though the medicine isn't yet approved for use by any regulatory authorities, Gilead is taking the step of of expanding production to increase supply.
- "As a result we have reduced the end-to-end manufacturing timeline from approximately one year, to around six months," O'Day wrote.
- Its existing supply, including finished product and investigational medicine in final stages of production, amounts to 1.5M individual doses, which could equate to more than 140,000 treatment courses for patients.
- Gilead is providing all of its existing supply at no cost to treat patients with the most severe symptoms of COVID-19.
- Sets a goal of producing more than 500,000 treatment courses by October and more than 1M treatment courses by the end of the year.
- Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, has recommended that in order to be prepared for COVID-19 becoming a seasonal occurrence, drug manufacturers should take the risk to ramp up production of therapeutics before phase 2 trials begin.
- Previously: Gilead's remdesivir OK'd in Europe for compassionate use in COVID-19 (April 3)
Recommended For You
More Trending News
See More »